Is the price fair?
What SUPN's price assumes
Today's price asks for 12% free cash flow growth a year; over the last three years Supernus Pharmaceuticals, Inc. delivered −20%, the price is ahead of the record.
3.84
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.2%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered −20% a year over the last three.
- Price / book
- 2.77
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.77
- EV / EBIToperating margin −7.8%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $82M
- Market capitalisation
- $2.58B
- 3-year revenue growth
- +5.1%
- 3-year free cash flow growth
- −20%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #19 of 28 by Smart Score